Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep;169(2):186-9.
doi: 10.1007/s00213-003-1492-0. Epub 2003 Apr 29.

Hypericum perforatum attenuates nicotine withdrawal signs in mice

Affiliations

Hypericum perforatum attenuates nicotine withdrawal signs in mice

Maria A Catania et al. Psychopharmacology (Berl). 2003 Sep.

Abstract

Rationale: Hypericum perforatum is used as a natural antidepressant, and other antidepressants have been marketed to aid in smoking cessation.

Objective: We investigated the effects of an extract of Hypericum perforatum (Ph-50) on withdrawal signs produced by nicotine abstinence in mice.

Methods: Nicotine (2 mg/kg, four injections daily) was administered for 14 days to mice. Different doses of Ph-50 (125-500 mg/kg) were administered orally immediately after the last nicotine injection. In another experiment, Ph-50 (500 mg/kg) was orally administered in combination with nicotine, i) starting from day 8 until the end of the nicotine treatment period, or ii) during nicotine treatment and after nicotine withdrawal, or iii) immediately after the last nicotine injection. On withdrawal from nicotine, all animals were evaluated for locomotor activity and abstinence signs.

Results: The locomotor activity reduction induced by nicotine withdrawal was abolished by Ph-50, which also significantly and dose-dependently reduced the total nicotine abstinence score when injected after nicotine withdrawal.

Conclusions: These data show that treatment with Hypericum perforatum attenuates nicotine withdrawal signs in mice. Further studies are necessary to test the possibility that it may be used for smoking cessation treatment in humans.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Harv Rev Psychiatry. 2000 Sep;8(3):99-110 - PubMed
    1. Am J Health Promot. 2002 Jul-Aug;16(6):323-30 - PubMed
    1. Pharmacol Biochem Behav. 2001 Feb;68(2):187-97 - PubMed
    1. Am J Psychiatry. 2002 Jun;159(6):947-53 - PubMed
    1. Psychopharmacology (Berl). 1995 Jan;117(1):2-10; discussion 14-20 - PubMed

LinkOut - more resources